Acute hyperhomocysteinemia decreases NO bioavailability in healthy adults

Atherosclerosis
Silvana C RomerioWalter E Haefeli

Abstract

Hyperhomocysteinemia is associated with decreased vascular reactivity and increased cardiovascular morbidity. Oxidative stress and reduced NO bioavailability have been proposed as a mechanism for the adverse effects of chronically elevated plasma homocysteine levels. Recent studies suggest that acute elevations of plasma homocysteine may also impair endothelial function and vasodilation, however, the mechanism is not clear. In the present study, we investigated whether moderate hyperhomocysteinemia after methionine loading decreases NO bioavailability, increases oxidative stress, and impairs receptor-mediated NO-dependent venodilation in healthy adults. After oral methionine loading (0.1g/kg), mean homocysteine concentrations increased 3.2-fold, from 6.9 +/- 0.5 to 27.8 +/- 1.9 micromol/l (n = 16), whereas plasma NO(x) concentrations, an indicator of NO release, were decreased by 12% compared to placebo treatment (P = 0.005). Vitamin E levels in freshly isolated low density lipoprotein (LDL), a sensitive marker of LDL oxidation, and LDL lipid (hydro)peroxide levels were unchanged after methionine loading. Endothelium-dependent venodilation induced by bradykinin was reduced by 18% during hyperhomocysteinemia (P = 0.06). Taken to...Continue Reading

References

Jan 1, 1992·The Journal of Clinical Investigation·J H ChinB B Hoffman
Oct 1, 1992·Free Radical Biology & Medicine·H EsterbauerG Jürgens
Dec 1, 1992·Clinical Pharmacology and Therapeutics·W E HaefeliT F Blaschke
Apr 25, 1991·The New England Journal of Medicine·R ClarkeI Graham
Nov 1, 1990·Journal of the American College of Cardiology·J J GenestM R Malinow
Apr 17, 1995·Biochemical and Biophysical Research Communications·P RhodesP ] Rhodes PM [corrected to Rhodes
Mar 21, 1996·The New England Journal of Medicine·M den HeijerF R Rosendaal
Jul 1, 1996·The Journal of Clinical Investigation·S R LentzD D Heistad
Jul 1, 1996·The Journal of Clinical Investigation·J Loscalzo
Sep 26, 1996·The New England Journal of Medicine·M CattaneoP M Mannucci
Oct 1, 1996·Clinical Pharmacology and Therapeutics·W M StrobelW E Haefeli
May 1, 1996·Journal of Vascular Research·R Busse, I Fleming
Mar 1, 1997·Journal of Applied Physiology·L JungerstenA Wennmalm
May 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·P VerhoefH Refsum
Jan 20, 1998·Lancet·J C ChambersJ S Kooner
Jun 15, 1999·JAMA : the Journal of the American Medical Association·F NappoD Giugliano
Dec 1, 1999·Clinical Pharmacology and Therapeutics·S C RomerioW E Haefeli
Oct 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·N WeissJ Loscalzo
Aug 1, 1959·Canadian Journal of Biochemistry and Physiology·E G BLIGH, W J DYER

❮ Previous
Next ❯

Citations

Jan 25, 2007·Clinical Chemistry and Laboratory Medicine : CCLM·Yeşim OzkanBolkan Simşek
Aug 8, 2012·Journal of Human Reproductive Sciences·Madhu JainShuchi Jain
Jan 1, 2009·International Journal of Alzheimer's Disease·Inara J ChacónGladys E Maestre
Feb 26, 2013·Nutrition·Ioanna EleftheriadouNicholas Tentolouris
Jan 24, 2007·Parkinsonism & Related Disorders·Nils HenningerMartin Krause
Aug 23, 2011·International Wound Journal·Mansooreh BagheriAli Zamani
Jan 16, 2014·European Journal of Clinical Investigation·Jacqueline M HornstraYvo M Smulders
Feb 28, 2014·Cardiovascular Therapeutics·Balazs Debreceni, Laszlo Debreceni
Jan 31, 2006·Free Radical Biology & Medicine·Helen R GriffithsHilary J Powers
Nov 10, 2012·Reproductive Sciences·Kiran Singh, Deepika Jaiswal
Feb 20, 2007·Human Reproduction Update·Thierry ForgesJ L Guéant
Oct 23, 2012·Hospital Practice·Andrea D MaderalRobert S Kirsner
Jun 9, 2005·Metabolic Brain Disease·Francieli M StefanelloAngela T S Wyse
Sep 3, 2017·Bioscience Reports·Lemen PanYinghua Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.